Avita Medical announces FDA approval of RECELL GO

AVITA Medical announced that the U.S. Food and Drug Administration has approved its premarket approval supplement for the RECELL GO System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects. In the United States, the Company will launch RECELL GO in its top burn treatment centers in June, and other existing accounts will be converted to RECELL GO throughout the year. New accounts will receive RECELL GO with their first order, eliminating the need for conversion. The supplement follows the original PMA of RECELL Autologous Cell Harvesting Device and subsequent PMA supplements.